Source comparison
Sermorelin vs Tesamorelin
Both sermorelin and tesamorelin are GHRH receptor agonists — they ring the same doorbell on the same pituitary cells. The differences lie in structure, potency, evidence base, and regulatory status. Structural difference: Sermorelin is the first 29 amino acids
This comparison does not assign a generated winner or score.
- Both sermorelin and tesamorelin are GHRH receptor agonists — they ring the same doorbell on the same pituitary cells. The differences lie in structure, potency, evidence base, and regulatory status.
- Structural difference: Sermorelin is the first 29 amino acids of GHRH (GRF 1-29) with no structural modifications. Tesamorelin retains the full 44-amino-acid GHRH sequence and adds a trans-3-hexenoic acid group to the N-terminus, which protects it against enzymatic degradation by DPP-IV (dipeptidyl peptidase-IV, the enzyme that rapidly breaks down native GHRH)¹³˒¹⁴. This gives tesamorelin modestly better metabolic stability, though both compounds have short half-lives in the range of 10-38 minutes.
- Evidence gap: The clinical evidence difference is stark. Tesamorelin has two Phase III RCTs totaling 816 patients with CT-measured visceral fat outcomes. Sermorelin has one adult trial with 19 subjects⁷˒⁸˒¹⁴. For anyone making evidence-based decisions, this gap is the primary differentiator.
- Regulatory status: Tesamorelin is currently FDA-approved (brand name Egrifta) for HIV-associated lipodystrophy. Sermorelin was FDA-approved but is commercially withdrawn. Both are legally compoundable, though through slightly different regulatory pathways.
- Tolerability: Edema and tingling were recorded less frequently with sermorelin than with tesamorelin’s more robust GH stimulation¹.
- The practical question: If tesamorelin has the stronger evidence, what accounts for sermorelin’s continued use? Three factors recur in the practitioner literature: (1) the lower edema and tingling frequency in edema-sensitive individuals, (2) lower cost through compounding pharmacies, and (3) a milder GH stimulus that fits goals short of maximal potency — recovery support during moderate caloric restriction, for example, rather than aggressive visceral fat reduction.
- For a comprehensive comparison across the full GH secretagogue class, see our GH secretagogue comparison guide.